Legislation introduced to combat spiralling US drugs prices

15 June 2016
drugs_pills_tablets_big

The US Senate Judiciary Committee introduced new legislation Tuesday, aimed at countering the growing issue of rising prescription drug prices in the USA and anti-competitive moves by pharmaceutical companies to delay lower-priced generic competition from entering the market.

The move introduces laws aimed at countering two key 'delaying' tactics often used by certain leading brand-name drugmakers in an alleged bid to protect their profits for as long as possible and gain maximum return on their research and development investments.

The Committee, led by Democrat Vermont Senator Patrick Leahy, brought in the bipartisan Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, which will prevent brand drugmakers from withholding the drug samples required by generic manufacturers to test for equal efficacy and safety to the original, and ultimately gain regulatory approval from the Food and Drug Administration.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics